Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Thomas Jefferson University
PharmaEssentia Japan K.K.
Incyte Corporation
Roswell Park Cancer Institute
City of Hope Medical Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hoffmann-La Roche
Hoffmann-La Roche
CTI BioPharma
Roswell Park Cancer Institute
Novartis
Icahn School of Medicine at Mount Sinai
CTI BioPharma
M.D. Anderson Cancer Center
University of Oklahoma
Novartis
Fred Hutchinson Cancer Center
Mayo Clinic
Italfarmaco
Italfarmaco
Roswell Park Cancer Institute
Italfarmaco
Novartis
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Incyte Corporation
University of Illinois at Chicago
M.D. Anderson Cancer Center
Wake Forest University Health Sciences
Incyte Corporation
OHSU Knight Cancer Institute
UNC Lineberger Comprehensive Cancer Center
Weill Medical College of Cornell University
Fred Hutchinson Cancer Center
Fred Hutchinson Cancer Center
Alliance for Clinical Trials in Oncology
University of Chicago
Mayo Clinic
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI)
INSYS Therapeutics Inc
Vanderbilt-Ingram Cancer Center